Wuxi Biologics Stock Price, News & Analysis

WuXi Biologics (2269.HK) has launched EffiX™, a proprietary E. coli expression system designed for high-yield production of recombinant proteins and plasmid DNA. The platform achieves exceptional yields of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA.

The technology addresses growing market demand for microbial-derived products including antibody fragments, nanobodies, enzymes, cytokines, antigens, polypeptides, and plasmid DNA. EffiX™ offers streamlined processes from research through commercial manufacturing, providing a comprehensive Chemistry, Manufacturing, and Controls (CMC) strategy for biotherapeutics development.

The platform is part of WuXi Biologics' integrated technology ecosystem, supporting early-stage research, CMC development, and GMP manufacturing for next-generation therapies.

WuXi Biologics (2269.HK) has successfully passed a GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities MFG2 and MFG5 in Wuxi city. The inspection, which evaluated the facilities' quality processes and production system, concluded without issues.

The company has now achieved a total of 42 regulatory inspections and received 97 license approvals from drug administration agencies across multiple countries including the U.S., Europe, China, Singapore, Japan and Canada. This track record demonstrates the company's compliance with global regulatory standards and robust quality system.

WuXi Biologics (2269.HK) has received the Platinum Medal from EcoVadis Sustainability Rating for the second consecutive year, placing it among the top 1% of over 150,000 companies evaluated across 185 countries. The rating assesses seven management indicators across 21 sustainability criteria in four main areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.

As a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi Biologics has demonstrated strong commitment to sustainability and ESG excellence. The company participates in the United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), earning multiple recognitions including:

• UNGC 20 Case Examples of Sustainable Development recognition
• MSCI AAA Rating
• Inclusion in Dow Jones Sustainability Indices
• Sustainalytics industry and regional ESG top-rated company status
• CDP Water Security 'A list' and Climate Change 'A-' score
• FTSE4Good Index Series constituent
• Hang Seng ESG 50 Index listing

WuXi Biologics (2269.HK) has been named a 2025 Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for the fifth consecutive year, ranking in the top 1% of pharmaceutical companies assessed. This recognition comes from Sustainalytics' evaluation of over 15,000 companies across 42 industries worldwide.

The company has achieved several notable ESG milestones, including:

• Inclusion in the UNGC 20 Case Examples of Sustainable Development
• MSCI AAA Rating and inclusion in Dow Jones Sustainability Indices
• EcoVadis Platinum Medal
• CDP Water Security 'A list' and 'A-' Climate Change score
• Selection as FTSE4Good Index Series Constituent
• Listing in Hang Seng ESG 50 Index

As a global Contract Research, Development and Manufacturing Organization (CRDMO), WuXi Biologics operates with over 12,000 employees across China, the United States, Ireland, Germany and Singapore, supporting 817 integrated client projects, including 21 in commercial manufacturing.

WuXi Biologics has announced an agreement with Candid Therapeutics granting Candid exclusive global rights to a preclinical trispecific T-cell Engager developed using WuXi's WuXiBody™ platform. Under the agreement, WuXi Biologics will receive an upfront payment plus development and sales milestones totaling up to $925 million along with royalties.

The collaboration marks WuXi's seventh global program for molecules discovery through their Research platform in 2024, with eligible near-term payments of around $140 million and total potential payments exceeding $2.3 billion. The WuXiBody™ platform has been upgraded to deliver customized multispecific antibodies, offering advantages like high expression yield, stability, good solubility, and expedited development timeframes of 6-18 months with reduced manufacturing costs.

WuXi Biologics (2269.HK) has been named to the 2024 Dow Jones Sustainability Indices (DJSI) for the second consecutive year, receiving top scores for its sustainable development achievements. The DJSI World represents the top 10% of 2,500 largest companies in the S&P Global Broad Market Index, based on ESG performance.

As a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi Biologics has garnered several sustainability recognitions, including:

• Inclusion in UNGC 20 Case Examples of Sustainable Development
• AAA rating from MSCI ESG Ratings for two consecutive years
• Platinum Medal from EcoVadis
• Industry and Regional Top-Rated Company by Sustainalytics
• CDP Water Security 'A list' and 'A-' Climate Change score
• Selection as FTSE4Good Index Series Constituent
• Inclusion in Hang Seng ESG 50 Index

WuXi Biologics (2269.HK) has been included in the United Nations Global Compact's '20 Case Examples for 20 Years: Private Sector's Sustainable Development in China' report, highlighting its commitment to sustainable development and green biologics solutions. The company was recognized for its implementation of green technology across its operations, featuring proprietary platforms like WuXiBody™ for green research, WuXiUI™ for ultra-intensified fed-batch production, and WuXiUP™ for continuous processing.

The company has received multiple ESG recognitions, including an AAA rating from MSCI ESG Ratings, inclusion in the DJSI World Index, a Platinum Medal from EcoVadis, and selection for the Hang Seng ESG 50 Index. These achievements reflect WuXi Biologics' successful integration of sustainable practices while maintaining its position as a leading global Contract Research, Development, and Manufacturing Organization.

WuXi Biologics announced significant achievements at its Dundalk, Ireland facility, including successful completion of multiple 16,000-liter Process Performance Qualification (PPQ) runs and GMP approvals from HPRA for all three manufacturing facilities. The site achieved two PPQ runs with 100% success rate using innovative single-use technology, combining four 4,000-liter bioreactors to match the performance of traditional stainless-steel systems.

The facility, operational since March 2022, employs over 760 people and features three manufacturing suites: a 6,000L perfusion suite and a 48,000L fed-batch suite. The site received the ISPE Facility of the Year Award in 2023 and holds ISO certifications for energy management, environmental management, and occupational safety.

WuXi Biologics announced plans to enhance its drug product capabilities at its Leverkusen, Germany facility with a new sterile filling line for prefilled syringes (PFS). The new line will handle multiple syringe sizes at up to 400 syringes per minute, with an annual capacity of 17 million syringes. This adds to the existing filling and freeze-drying line's capacity of 10 million doses annually. Construction will begin recently with GMP compliance targeted for 2026. The expansion supports WuXi Bio's Global Dual Sourcing strategy and aims to meet growing client demand for drug product services.